Table 2.
Utilization of heart failure medications at baseline
| HF medications | Patients on HF medications (%) | Patients on ≥ 50% MTD HF medication (%) | Mean % MTD |
|---|---|---|---|
| ACEI/ARB/ARNI | 100 | 45 | 44.4 ± 31.7 |
| ARNI | 55 | 15 | 20.6 ± 30.9 |
| ACEI/ARB | 45 | 30 | 23.8 ± 32.9 |
| MRA | 70 | 25 | 25.0 ± 19.9 |
| Beta-blocker | 90 | 35 | 34.1 ± 29.6 |
| Ivabradine | 20 | 5 | 8.3 ± 4.1 |
| SGLT inhibitor | 55 | 55 | 55.0 ± 51.0 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor and neprilysin inhibitor; HF, heart failure; MRA, mineralocorticoid receptor antagonist; MTD, maximal target dose; SGLT, sodium glucose cotransporter.